StopDown
Results · 28 July 2026Tata 1mgDigital healthcare platform

Tata 1mg revenue FY26: Rs 2,936 Cr, net loss Rs 287 Cr

Tata 1mg revenue nears Rs 3,000 Cr with narrowing loss

By · Editor ·

Tata 1mg revenue

Tata 1mg reported revenue of Rs 2,936 Cr in FY26, with a net loss of Rs 287 Cr, as reported by Entrackr on 28 July 2026.

Tata 1mg revenue
Revenue (FY26)Rs 2,936 Cr
Net loss (FY26)Rs 287 Cr
  • Tata 1mg is a digital healthcare platform selling medicines and diagnostics online
  • FY26 revenue reached Rs 2,936 Cr while net loss narrowed to Rs 287 Cr
  • The company faces competition from Netmeds, PharmEasy, and Apollo 24/7 in the market

What happened

  • Tata 1mg reported FY26 consolidated revenue of Rs 2,936 Cr, up 23% from FY25.
  • The company's net loss narrowed to Rs 287 Cr for the fiscal year 2026.
  • Revenue split showed Rs 2,440 Cr from Healthcare Solutions and Rs 496 Cr from Technologies.
  • Tata 1mg Healthcare Solutions posted a loss of Rs 310 Cr during the period.
  • Tata 1mg Technologies contributed a profit of Rs 23 Cr to the combined results.
  • Total assets stood at Rs 2,268 Cr with liabilities totaling Rs 1,601 Cr.
  • Reserves remained negative at Rs 167 Cr due to significant losses in the healthcare entity.
  • Tata Digital acquired a majority stake in 1mg in June 2021 to expand its ecosystem.

Why it matters

  • Tata Digital group revenue grew 12% to Rs 35,990 Cr in FY26.
  • The parent group's net loss widened to Rs 4,974 Cr from the previous year.
  • Tata Digital GMV reached Rs 46,515 Cr indicating strong transaction volumes across sectors.

The business

  • The platform sells allopathic, ayurvedic, and homeopathic medicines through its online store.
  • It offers vitamins, nutrition supplements, and general healthcare products to consumers.
  • Diagnostics services form a key part of its healthcare service offerings.
  • The company operates under two entities: Healthcare Solutions and Technologies.
  • Healthcare Solutions drives the majority of revenue and asset base.
  • Technologies contributes smaller revenue but remains profitable independently.
  • The business model relies on digital distribution of medical products.
  • It competes directly with other major online pharmacy players in India.

In numbers

Rs 2,936 CrConsolidated Revenue · FY26
Rs 287 CrNet Loss · FY26
Rs 2,440 CrHealthcare Solutions Revenue · FY26
Rs 23 CrTechnologies Profit · FY26
Rs 2,268 CrTotal Assets · FY26

Up against

Reliance-backed NetmedsPharmEasyApollo 24/7

The numbers around it

Healthcare & Life Sciences in July 2026: 11 rounds with a disclosed amount, $87.1 million in all; the biggest was Iswarya (Rs 350 crore). Every sector this year →

Read it as a card in the app

Terms in this story

  • Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.

Everything on Tata 1mg → · All startup news on 28 July 2026 →

Is this Tata 1mg? Get your “Featured on StopDown” badge →